Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

18.50
+1.478.63%
Pre-market: 18.40-0.1000-0.54%07:08 EST
Volume:3.17M
Turnover:58.08M
Market Cap:1.94B
PE:-6.68
High:18.64
Open:17.59
Low:17.51
Close:17.03
52wk High:114.41
52wk Low:10.42
Shares:104.79M
Float Shares:95.17M
Volume Ratio:1.04
T/O Rate:3.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7711
EPS(LYR):2.34
ROE:-21.37%
ROA:-1.52%
PB:1.47
PE(LYR):7.91

Loading ...

Arrowhead   Pharmaceuticals  misses Q1 revenue estimates

Reuters
·
Feb 06

BUZZ-U.S. STOCKS ON THE MOVE-Bio-Techne, AbbVie, Johnson Controls

Reuters
·
Feb 04

BRIEF-Sarepta Therapeutics Announces Clinical Trial Application Approval For SRP-1005 In Huntington’s Disease

Reuters
·
Feb 04

Sarepta Therapeutics Wins New Zealand Approval for First-in-Human SRP-1005 Trial

Reuters
·
Feb 04

Sarepta Therapeutics Announces Approval of Clinical Trial Application for Srp-1005, Its Investigational Treatment for Huntington’s Disease

THOMSON REUTERS
·
Feb 04

Sarepta Therapeutics Inc: First-in-Human Clinical Study of Srp-1005, Known as Insightt, Is Expected to Begin in Q2 of 2026

THOMSON REUTERS
·
Feb 04

Sarepta assumed with an Equal Weight at Barclays

TIPRANKS
·
Jan 28

Sarepta price target raised to $22 from $15 at Baird

TIPRANKS
·
Jan 27

Sarepta Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 27

H.C. Wainwright reiterates Sell on Sarepta after 3-year data

TIPRANKS
·
Jan 27

Sarepta Therapeutics Inc : Baird Raises Target Price to $22 From $15

THOMSON REUTERS
·
Jan 27

Sarepta Therapeutics, Lands' End, USA Rare Earth, CoreWeave And Other Big Stocks Moving Higher On Monday

Benzinga_recent_news
·
Jan 27

BUZZ-U.S. STOCKS ON THE MOVE-US natgas companies

Reuters
·
Jan 26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (SRPT) and InMode (INMD)

TIPRANKS
·
Jan 26

Sarepta rises 14.1%

TIPRANKS
·
Jan 26

Sarepta Therapeutics Shares Rise 6.7% Premarket After Co Reports Three-Year Data for Duchenne Muscular Dystrophy Gene Therapy

THOMSON REUTERS
·
Jan 26

Sarepta's Duchenne gene therapy slows disease progression at three years

Reuters
·
Jan 26

Sarepta reports ‘positive’ topline three-year EMBARK results for Elevidys

TIPRANKS
·
Jan 26

Sarepta Therapeutics Inc - No New Safety Signals Observed for Elevidys

THOMSON REUTERS
·
Jan 26

Sarepta Therapeutics Inc - Elevidys Shows 70% Reduction in Disease Decline Rate

THOMSON REUTERS
·
Jan 26